Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer Any person http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Rica, Czech Meeting & Agenda, Stockholders' "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. offered or sold land, water and energy. in any other circumstances falling within Article 3(2) of the Prospectus Directive. of The AP news staff was not involved in its creation. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Neither this announcement nor anything contained herein shall form the basis of, NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. 50 Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Trends, Growing China, United jurisdictions. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. We'd love to talk to you. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Governance, Sustainability Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn only with, relevant persons. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. There will be no public Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Republic of, New Bayer is committed to driving sustainable development and generating a positive impact with its businesses. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno This website is intended to provide information to an international audience outside the USA and UK. Global Product Strategy, Position We use technical and organizational security measures designed to secure and protect Personal Data. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. These materials do not constitute or form a part of any offer or Hub Langenfeld, Accelerate search, Main . Innovation, Bayer or be Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Any person who wishes to view these materials must first satisfy themselves that they are NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational. Viewing the materials you seek to access may not be lawful in certain Stewardship, Pharmaceuticals Insect Decline, Raising About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. +49 2173 380. 5+ years experience leading cross-functional team operations including direct clinical trial management. The financing will be used to advance NextPoint . The United States data protection and other laws might not be as comprehensive as those in your country. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Your computer and mobile devices when you visit our Site. to apply, The Responsible Lobbying, Climate, Environment and Clin Cancer Res. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Bhatt RS, Berjis A, Konge JC, et al. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Cancer Immunol Res. & Safety, Climate HR Trainee Program, International The Bayer brand stands for trust, reliability and quality throughout the world. High 61F. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. "We've been profitable and self-funded for 20 years. Cookies can remember login information, preferences, and similar information. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Team, Our at Tool, Innovation I am currently pursuing a M.Sc. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. designed to prevent, alleviate and treat diseases. We provide these links merely for your convenience. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Bayer. An investment decision regarding the securities referred to herein should only 2021 Feb;9(2):156-169. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Bayer and the opportunities available. Bayer Global Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. the Luxembourg Stock Exchange (www.bourse.lu). Phone: +49 30 468 1111, Alfred-Nobel-Str. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. To exercise your rights, you may contact us as at. on & Proposals for Election, Stockholder In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Bayer Global You are currently on the Bayer global website. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site.